AnaptysBio, Inc.
ANAB
$17.17
$0.935.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 91.28M | 57.17M | 30.47M | 22.96M | 17.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.28M | 57.17M | 30.47M | 22.96M | 17.16M |
| Cost of Revenue | 163.84M | 154.78M | 143.44M | 134.37M | 132.28M |
| Gross Profit | -72.56M | -97.60M | -112.97M | -111.41M | -115.13M |
| SG&A Expenses | 42.39M | 42.47M | 42.08M | 43.47M | 41.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.23M | 197.25M | 185.52M | 177.83M | 174.23M |
| Operating Income | -114.95M | -140.08M | -155.05M | -154.87M | -157.07M |
| Income Before Tax | -145.23M | -165.65M | -170.11M | -163.30M | -163.62M |
| Income Tax Expenses | 3.00K | 5.00K | 5.00K | -4.00K | -4.00K |
| Earnings from Continuing Operations | -145.23 | -165.66 | -170.12 | -163.30 | -163.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -145.23M | -165.66M | -170.12M | -163.30M | -163.62M |
| EBIT | -114.95M | -140.08M | -155.05M | -154.87M | -157.07M |
| EBITDA | -114.34M | -139.45M | -154.41M | -154.22M | -156.42M |
| EPS Basic | -5.20 | -6.07 | -6.34 | -6.13 | -6.07 |
| Normalized Basic EPS | -3.25 | -3.62 | -3.79 | -3.66 | -3.62 |
| EPS Diluted | -5.20 | -6.07 | -6.34 | -6.13 | -6.07 |
| Normalized Diluted EPS | -3.25 | -3.62 | -3.79 | -3.66 | -3.62 |
| Average Basic Shares Outstanding | 113.50M | 109.64M | 107.29M | 106.56M | 107.71M |
| Average Diluted Shares Outstanding | 113.50M | 109.64M | 107.29M | 106.56M | 107.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
